Arovella Therapeutics (ASX: ALA) has strengthened its clinical development team ahead of the company’s planned first-in-human trial for ALA-101 | Announcement:
cdn-api.markitdigital.com/ap…@WeAreArovella$ALA
Greenvale Energy (ASX:GRV) has provided an update on Test Program 7 (TP7) at its Alpha Project. Project characterisation work at the Alpha Project has now been completed by New Zealand-based Technix | Announcement:
announcements.asx.com.au/asx…@GreenvaleGrv$GRV
_ @OncoSil_Medical (ASX:OSL) has announced that the TRIPP-FFX study abstract has been selected for a Rapid Oral Presentation at ESMO GI 2026, one of the world's leading gastrointestinal cancer conferences.
ASX announcement: announcements.asx.com.au/asx…
dorsaVi (ASX:DVL) has completed a strategic analysis, which indicates its resistive random-access memory (RRAM) and neuromorphic computing roadmap could more than double battery life in exoskeleton and wearable robotics applications | announcements.asx.com.au/asx…@dorsavi$DVL
_ @EBRSystemsInc (ASX: EBR) has completed the institutional component of its ~A$150m fully underwritten raise, raising ~A$106.4m with strong support. The retail entitlement offer is fully underwritten and expected to raise ~A$43.6m.
ASX announcement: announcements.asx.com.au/asx…
FortifAI Limited (ASX: FTI) has appointed Silicon Valley technology executive Kelly Herrell as its new Chief Executive Officer. He will lead efforts by FortifAI and its AI infrastructure subsidiary Nol8 | Announcement: announcements.asx.com.au/asx…#fortifAI$FTI
_ @EBRSystemsInc (ASX:EBR) has achieved a major reimbursement milestone, with the U.S. Centers for Medicare & Medicaid Services (CMS) initiating a National Coverage Determination (NCD) process for the WiSE® System.
ASX announcement: announcements.asx.com.au/asx…
_ @Optiscan_ (ASX:OIL) has reached the halfway milestone in its first in-human breast cancer imaging study at The Royal Melbourne Hospital.
ASX announcement: announcements.asx.com.au/asx…
_ @4DMedicalXV (ASX:4DX) launched CLEAR, a clinical evidence program to accelerate CT:VQ™ into acute PE, expanding US opportunity to ~US$3bn.
Webinar – 11:00am AEST Tue 9 June 2026. CEO Dr Andreas Fouras hosts live Q&A.
Register: s1.c-conf.com/diamondpass/10…
_ @Optiscan_ (ASX:OIL) has announced the second anniversary of its Know-How Agreement with Mayo Clinic, marking continued progress in the co-development of a robotic-compatible digital endomicroscopic imaging system for surgery.
ASX announcement: announcements.asx.com.au/asx…
_ @4DMedicalXV (ASX:4DX) has announced a major expansion into Europe through the acquisition of Austrian medical technology company contextflow, establishing an immediate commercial and clinical platform across the region.
ASX announcement: announcements.asx.com.au/asx…
EV Resources Limited (ASX:EVR) has achieved a major permitting milestone at its Tecomatlán Processing Plant in Puebla, Mexico, advancing the company’s pathway toward near-term antimony production | Announcement:
announcements.asx.com.au/asx…@EVResources_EVR$EVR
Epiminder (ASX:EPI) has reached a key milestone in its DETECT clinical study, announcing the enrolment of its 25th patient as momentum continues to build across the United States.
ASX announcement: cdn-api.markitdigital.com/ap…
_ @OncoSil_Medical (ASX:OSL) has secured key ethics approval in Italy for its OSPRItaly post-market clinical registry, supporting a broader commercial rollout of the OncoSil™ device across this major European country.
ASX announcement: announcements.asx.com.au/asx…
Acrux (ASX:ACR) has expanded its licensing agreement with Gedeon Richter Plc for Lenzetto® in the Australian market.
ASX announcement: cdn-api.markitdigital.com/ap…
Alcidion Group (ASX:ALC) has signed a seven-year contract with University Hospitals Sussex NHS Foundation Trust to deploy its Miya Precision Electronic Patient Record (EPR) platform | Announcement:
cdn-api.markitdigital.com/ap…@alcidion$ALC
_ @OncoSil_Medical (ASX:OSL) says Spanish clinical experience with the OncoSil™ device has been accepted for poster presentation at the 2026 ASCO Annual Meeting in Chicago, highlighting growing recognition in unresectable LAPC.
announcements.asx.com.au/asx…